Given the recurrence of p53 mutation and the increased GRK2 expression and activity in thyroid carcinomas, we explored the feasibility of our hypothesis in a p53-mutated thyroid cancer cell line (BHT-101) using a p53-null cell line (FRO) as a control. The gene discussed is GRK2; the disease is thyroid cancer.